Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

FOUND: Chimerix shares plummet after divesting its only marketed product for over 300m | Mind Blowing Facts

  • Emergent BioSolutions Inc (NYSE:EBS) has agreed to acquire Chimerix Inc's (NASDAQ:CMRX) exclusive worldwide rights to Tembexa (brincidofovir), the first FDA-approved antiviral for all age groups for smallpox. 
  • "It exemplifies our thoughtful M&A strategy as part of our 2024 growth plan and positions us better to deliver value for our shareholders," said Robert Kramer, president & CEO of Emergent. 
  • Also See: Chimerix's CMX521 Antiviral Program Shows Potential Against COVID-19 In Preclinical Studies.
  • "This transaction expands and further diversifies our medical countermeasures business with the addition of a small molecule therapeutic that aligns with the government's smallpox preparedness strategy," said Paul Williams, SVP government/MCM business at Emergent. 
  • "It is expected to be accretive upon first product delivery under the anticipated BARDA contract within three to six months from closing," Williams added.
  • Emergent will pay Chimerix a $225 million one-time upfront payment in cash upon closing and up to $100 million in milestone payments contingent on the potential exercise by the U.S. government of procurement options. 
  • Emergent closed the March quarter with a cash balance of $435.8 million.
  • Chimerix remains eligible to receive a portion of the regulatory milestone payments associated with the license to SymBio Pharmaceuticals Ltd for indications other than orthopoxvirus infections.
  • Price Action: CMRX shares plunge 57.1% to $1.82 during the market session on the last check Monday.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.